A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation - PubMed (original) (raw)
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation
L G Kostrikis et al. Nat Med. 1998 Mar.
Abstract
Viral and host factors influence the rate of HIV-1 disease progression. For HIV-1 to fuse, a CD4+ cell must express a co-receptor that the virus can use. The chemokine receptors CCR5 and CXCR4 are used by R5 and X4 viruses, respectively. Most new infections involve transmission of R5 viruses, but variants can arise later that also use CXCR4 (R5-X4 or X4 viruses). This is associated with an increased rate of CD4+ T-cell loss and poor prognosis. The ability of host cells to support HIV-1 entry also influences progression. The absence of CCR5 in approximately 1% of the Caucasian population, due to homozygosity for a 32-nucleotide deletion in the coding region (delta32-CCR5 allele), very strongly protects against HIV-1 transmission. Heterozygosity for the delta32-CCR5 allele delays progression typically by 2 years. A recent study showed that a conservative substitution (V64I) in the coding region of CCR2 also has a significant impact on disease progression, but not on HIV-1 transmission. This was unexpected, since CCR2 is rarely used as a co-receptor in vitro and the V64I change is in a transmembrane region. Because a subsequent study did not confirm this effect on progression to disease, we analyzed CCR2-V64I using subjects in the Chicago MACS. We show that CCR2-V64I is indeed protective against disease progression and go on to show that the CCR2-V64I allele is in complete linkage disequilibrium with a point mutation in the CCR5 regulatory region.
Comment in
- Chemokine genes--beating the odds.
Stewart G. Stewart G. Nat Med. 1998 Mar;4(3):275-7. doi: 10.1038/nm0398-275. Nat Med. 1998. PMID: 9500597 No abstract available. - Genetic effects on HIV disease progression.
Ioannidis JP, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DG, Goedert JJ. Ioannidis JP, et al. Nat Med. 1998 May;4(5):536. doi: 10.1038/nm0598-536. Nat Med. 1998. PMID: 9585207 No abstract available.
Similar articles
- Better CD4+ T cell recovery in Brazilian HIV-infected individuals under HAART due to cumulative carriage of SDF-1-3'A, CCR2-V64I, CCR5-D32 and CCR5-promoter 59029A/G polymorphisms.
Rigato PO, Hong MA, Casseb J, Ueda M, de Castro I, Benard G, Duarte AJ. Rigato PO, et al. Curr HIV Res. 2008 Sep;6(5):466-73. doi: 10.2174/157016208785861131. Curr HIV Res. 2008. PMID: 18855658 - Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection.
Singh KK, Barroga CF, Hughes MD, Chen J, Raskino C, McKinney RE, Spector SA. Singh KK, et al. J Infect Dis. 2003 Nov 15;188(10):1461-72. doi: 10.1086/379038. Epub 2003 Nov 18. J Infect Dis. 2003. PMID: 14624371 - [Effects of CCR5-delta32, CCR2-64I and SDF-1-3'A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population].
Wasik TJ, Smoleń J, Kruszyński P, Bratosiewicz-Wasik J, Beniowski M. Wasik TJ, et al. Wiad Lek. 2005;58(9-10):500-7. Wiad Lek. 2005. PMID: 16529059 Polish. - HIV-1 Infection in Persons Homozygous for CCR5-Δ32 Allele: The Next Case and the Review.
Smoleń-Dzirba J, Rosińska M, Janiec J, Beniowski M, Cycoń M, Bratosiewicz-Wąsik J, Wąsik TJ. Smoleń-Dzirba J, et al. AIDS Rev. 2017 Dec;19(4):219-230. AIDS Rev. 2017. PMID: 28534889 Review. - HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.
Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP. Sheppard HW, et al. J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):307-13. doi: 10.1097/00126334-200203010-00013. J Acquir Immune Defic Syndr. 2002. PMID: 11873082 Review.
Cited by
- JAK/STAT signaling pathway affects CCR5 expression in human CD4+ T cells.
Wang L, Yukselten Y, Nuwagaba J, Sutton RE. Wang L, et al. Sci Adv. 2024 Mar 22;10(12):eadl0368. doi: 10.1126/sciadv.adl0368. Epub 2024 Mar 20. Sci Adv. 2024. PMID: 38507500 Free PMC article. - New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine.
Xu H, Lin S, Zhou Z, Li D, Zhang X, Yu M, Zhao R, Wang Y, Qian J, Li X, Li B, Wei C, Chen K, Yoshimura T, Wang JM, Huang J. Xu H, et al. Cell Mol Immunol. 2023 Jul;20(7):739-776. doi: 10.1038/s41423-023-01032-x. Epub 2023 May 17. Cell Mol Immunol. 2023. PMID: 37198402 Free PMC article. Review. - Genetic variation in the chemokine receptor 5 gene and course of HIV infection; review on genetics and immunological aspect.
Verma MK, Shakya S. Verma MK, et al. Genes Dis. 2020 Apr 18;8(4):475-483. doi: 10.1016/j.gendis.2020.04.007. eCollection 2021 Jul. Genes Dis. 2020. PMID: 34179311 Free PMC article. Review. - Opioid and neuroHIV Comorbidity - Current and Future Perspectives.
Fitting S, McRae M, Hauser KF. Fitting S, et al. J Neuroimmune Pharmacol. 2020 Dec;15(4):584-627. doi: 10.1007/s11481-020-09941-8. Epub 2020 Sep 2. J Neuroimmune Pharmacol. 2020. PMID: 32876803 Free PMC article. Review. - CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
Blackard JT, Kong L, Rouster SD, Karns R, Horn PS, Kottilil S, Shata MT, Sherman KE. Blackard JT, et al. PLoS One. 2019 Oct 29;14(10):e0224523. doi: 10.1371/journal.pone.0224523. eCollection 2019. PLoS One. 2019. PMID: 31661521 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous